BPS Bioscience, Inc. Announces New Metabolic Enzymes for Life Science Research

SAN DIEGO - May 14, 2013 - PRLog -- BPS Bioscience, Inc. (“BPS”) announces the release of over 20 different metabolic enzymes for drug discovery research in cancer, inflammation, diabetes, obesity, neurodegenerative disorders, and aging.

Metabolic enzymes make up the life-sustaining pathways that allow organisms to grow, reproduce, maintain homeostasis, and respond to their environments.  These vital metabolic pathways include proteolysis and digestion, cellular respiration, energy storage, transcriptional regulation, and other pathways essential for cellular integrity and survival.  Metabolic enzymes encompass a wide range of different protein classes, including carboxylases, dehydrogenases, lipoxygenases, oxidoreductases, kinases, lyases, transferases, and more.

Given the importance of these essential pathways to cellular integrity and survival, it is not surprising that disregulation of delicate metabolic pathways has been linked to a number of human diseases.   Targeting metabolic enzymes is of high interest in drug development programs for metabolic diseases such as diabetes, obesity and cancer.

BPS Bioscience is the first company to make many of these enzymes available to the life science research community.  BPS’s portfolio of metabolic enzymes currently includes 23 different enzymes, including Acetyl-coenzyme A carboxylases (ACC1 and ACC2) which play crucial roles in fatty acid metabolism in human and are identified as attractive targets against diabetes and obesity,  Phosphoglycerate Dehydrogenase (PHGDH) which has been identified as a marker for aggressive breast cancer and melanoma, Nicotinamide Phosphoribosyltransferase (also known as PBEF or Visfatin) which regulates insulin secretion and is linked to type 2 diabetes and tumor metastasis, ATP-citrate Lyase (ACLY) which is required for histone acetylation and is highly upregulated in cancer cells, and Isocitrate Dehydrogenase (IDH1), a tumor marker in leukemia and brain tumors.  Additional metabolic enzymes are planned for release in the coming months.  To learn more about BPS Bioscience’s entire portfolio of metabolic enzymes and related products please visit http://bpsbioscience.com/metabolic-enzymes.